85.10
0.75 (0.89%)
| Penutupan Terdahulu | 84.35 |
| Buka | 84.35 |
| Jumlah Dagangan | 12,389,113 |
| Purata Dagangan (3B) | 11,393,811 |
| Modal Pasaran | 146,440,159,232 |
| Harga / Pendapatan (P/E TTM) | 111.97 |
| Harga / Pendapatan (P/E Ke hadapan) | 43.67 |
| Harga / Jualan (P/S) | 10.85 |
| Harga / Buku (P/B) | 8.89 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 24 Mar 2026 |
| Margin Keuntungan | -1.00% |
| Margin Operasi (TTM) | 2.85% |
| EPS Cair (TTM) | -0.060 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 56.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 21.58% |
| Nisbah Semasa (MRQ) | 2.35 |
| Aliran Tunai Operasi (OCF TTM) | 1.29 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -113.22 M |
| Pulangan Atas Aset (ROA TTM) | -0.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -0.74% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | INNOVENT BIO | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.13 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| INNOVENT BIO | 146 B | - | 111.97 | 8.89 |
| WUXI BIO | 143 B | - | 31.10 | 2.84 |
| SINO BIOPHARM | 117 B | 1.15% | 27.21 | 2.85 |
| AKESO | 104 B | - | - | 13.98 |
| PHARMARON | 54 B | 0.92% | 20.42 | 2.23 |
| BEONE MEDICINES | 296 B | - | 663.87 | 7.45 |
|
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has 12 commercialized oncology products and three commercialized nononcology products as of March 2025. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Core |
| % Dimiliki oleh Orang Dalam | 6.49% |
| % Dimiliki oleh Institusi | 44.77% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |